Afton Scientific — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Afton Scientific is a privately held, revenue-generating CDMO focused on sterile injectable manufacturing. The company has built a strong reputation over its 16+ year history for robust regulatory compliance, a mature Quality Management System, and a 99.9% on-time delivery rate. It is currently executing a multi-year expansion to increase production capacity and integrate new filling technologies, positioning itself to meet growing global demand for outsourced aseptic manufacturing. Its business model is purely service-based, partnering with pharmaceutical companies rather than developing its own therapeutic pipeline.

Drug Delivery

Technology Platform

Integrated aseptic fill-finish and sterile manufacturing infrastructure, including advanced filling lines, single-use systems, and a comprehensive Quality Management System compliant with FDA and EU Annex 1 standards.

Opportunities

The global trend towards outsourcing sterile manufacturing, especially for complex biologics, provides a large and growing addressable market.

The company's ongoing capacity and technology expansion allows it to capture more of this demand and serve larger-scale commercial programs.

Increasing regulatory stringency (e.g., EU Annex 1) favors established CDMOs with robust, inspection-ready quality systems.

Risk Factors

High operational risk associated with aseptic processing, where a single contamination event or major regulatory observation could severely impact reputation and business.

Intense competition from larger, global CDMOs and other specialized sterile manufacturers pressures pricing and requires continuous capital investment.

Dependency on the health of the biotech funding environment, as a downturn can reduce demand for contract services.

Competitive Landscape

Afton Scientific competes in the crowded and competitive sterile fill-finish CDMO market. It faces competition from large, diversified global players (e.g., Lonza, Catalent, Recipharm), large pharmaceutical companies with excess CDMO capacity, and a range of other specialized U.S.-based contract manufacturers. Its competitive differentiation appears to be a focus on high-touch partnerships, a strong on-time delivery record, and a strategic investment in modern, compliant facilities.

More companies in Biologics / Biosimilars →More companies in United States →